Hofbauer LC et al. |
Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. |
2002 |
Eur. J. Endocrinol. |
pmid:12153751
|
Mundy GR |
Metastasis to bone: causes, consequences and therapeutic opportunities. |
2002 |
Nat. Rev. Cancer |
pmid:12154351
|
Lorget F et al. |
Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12163011
|
Ulrich-Vinther M et al. |
Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. |
2002 |
J Bone Joint Surg Am |
pmid:12177271
|
Ohmori H et al. |
Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. |
2002 |
J. Hum. Genet. |
pmid:12181640
|
Armstrong AP et al. |
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. |
2002 |
J. Biol. Chem. |
pmid:12185073
|
Zou W and Bar-Shavit Z |
Dual modulation of osteoclast differentiation by lipopolysaccharide. |
2002 |
J. Bone Miner. Res. |
pmid:12096834
|
Koyama H et al. |
Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. |
2002 |
J. Bone Miner. Res. |
pmid:12096835
|
Langdahl BL et al. |
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. |
2002 |
J. Bone Miner. Res. |
pmid:12096838
|
Zhang J et al. |
Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. |
2002 |
J. Bone Miner. Res. |
pmid:12096839
|
Treuheit MJ et al. |
Inverse relationship of protein concentration and aggregation. |
2002 |
Pharm. Res. |
pmid:12033388
|
Biskobing DM et al. |
Novel therapeutic options for osteoporosis. |
2002 |
Curr Opin Rheumatol |
pmid:12118183
|
Mizukami J et al. |
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. |
2002 |
Mol. Cell. Biol. |
pmid:11809792
|
Wynne F et al. |
Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. |
2002 |
Calcif. Tissue Int. |
pmid:12073153
|
Lubberts E et al. |
Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. |
2002 |
Arthritis Rheum. |
pmid:12428250
|
Crotti TN et al. |
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. |
2002 |
Ann. Rheum. Dis. |
pmid:12429533
|
Hofbauer LC and Schoppet M |
Osteoprotegerin deficiency and juvenile Paget's disease. |
2002 |
N. Engl. J. Med. |
pmid:12432053
|
Jono S et al. |
Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. |
2002 |
Circulation |
pmid:12208791
|
Sedger LM et al. |
Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. |
2002 |
Eur. J. Immunol. |
pmid:12209637
|
Stajszczyk M |
[Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. |
2002 |
Pol. Arch. Med. Wewn. |
pmid:12600190
|
Fahrleitner A et al. |
Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. |
2002 |
Wien. Klin. Wochenschr. |
pmid:12602117
|
Yang X et al. |
Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:11779130
|
Nosaka K et al. |
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. |
2002 |
Blood |
pmid:11781248
|
Takayanagi H |
[Cross-talk between immune and skeletal systems]. |
2002 |
Nippon Rinsho |
pmid:12510352
|
Shimizu-Ishiura M et al. |
Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. |
2002 |
J Electron Microsc (Tokyo) |
pmid:12455916
|
Saidenberg Kermanac'h N et al. |
Osteoprotegerin and inflammation. |
2002 Apr-Jun |
Eur. Cytokine Netw. |
pmid:12101070
|
Jung K et al. |
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. |
2002 Jul-Sep |
Int. J. Biol. Markers |
pmid:12408468
|
Chong B et al. |
Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. |
2003 |
J. Bone Miner. Res. |
pmid:14672344
|
Nielsen KL et al. |
Biglycan deficiency interferes with ovariectomy-induced bone loss. |
2003 |
J. Bone Miner. Res. |
pmid:14672350
|
Amizuka N et al. |
Defective bone remodelling in osteoprotegerin-deficient mice. |
2003 |
J Electron Microsc (Tokyo) |
pmid:14756238
|
Fizazi K et al. |
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. |
2003 |
Clin. Cancer Res. |
pmid:12855635
|
Kawana F and Sasaki T |
Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. |
2003 |
J Electron Microsc (Tokyo) |
pmid:14756239
|
Okuma K et al. |
Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. |
2003 |
J. Virol. |
pmid:12857926
|
Cheng X et al. |
The TNF receptor superfamily: role in immune inflammation and bone formation. |
2003 |
Immunol. Res. |
pmid:12857975
|
Shin MM et al. |
High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. |
2003 |
Exp. Mol. Med. |
pmid:12858015
|
Gehrke T et al. |
Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. |
2003 |
Scand. J. Rheumatol. |
pmid:14690142
|
Glossop JR et al. |
No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. |
2003 |
J. Rheumatol. |
pmid:12858434
|
Hampson G et al. |
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. |
2003 |
Osteoporos Int |
pmid:12904840
|
Stolina M et al. |
Regulatory effects of osteoprotegerin on cellular and humoral immune responses. |
2003 |
Clin. Immunol. |
pmid:14697750
|
Misra M et al. |
Serum osteoprotegerin in adolescent girls with anorexia nervosa. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915674
|
Lonergan M et al. |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915677
|
Kapczuk K et al. |
[Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. |
2003 |
Ginekol. Pol. |
pmid:12916277
|
Liu JZ et al. |
[Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. |
2003 |
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi |
pmid:12916296
|
Bendre MS et al. |
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. |
2003 |
Bone |
pmid:12919697
|
Tabb MM et al. |
Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. |
2003 |
J. Biol. Chem. |
pmid:12920130
|
Park HR et al. |
Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. |
2003 |
J. Korean Med. Sci. |
pmid:12923331
|
Kim HH et al. |
RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. |
2003 |
FASEB J. |
pmid:14500543
|
Nakamura M et al. |
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. |
2003 |
Endocrinology |
pmid:14500574
|
Zhang Z et al. |
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. |
2003 |
J. Immunol. |
pmid:14500659
|
Ueno Y et al. |
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. |
2003 |
J. Cell. Biochem. |
pmid:14505343
|
Kaneyama K et al. |
Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. |
2003 |
Int J Oral Maxillofac Surg |
pmid:14505625
|
Miyahira Y et al. |
Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. |
2003 |
J. Immunol. |
pmid:14662831
|
Seidlova-Wuttke D et al. |
Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. |
2003 |
Eur. J. Endocrinol. |
pmid:14514351
|
Hortobagyi GN |
Novel approaches to the management of bone metastases. |
2003 |
Semin. Oncol. |
pmid:14613037
|
Grigorie D et al. |
Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. |
2003 |
Rom J Intern Med |
pmid:15526523
|
Wagner EF and Matsuo K |
Signalling in osteoclasts and the role of Fos/AP1 proteins. |
2003 |
Ann. Rheum. Dis. |
pmid:14532157
|
Ueland T et al. |
Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. |
2003 |
Bone |
pmid:14555269
|
Nagata N et al. |
Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. |
2003 |
Bone |
pmid:14555278
|
Koshihara Y et al. |
Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. |
2003 |
J. Endocrinol. |
pmid:12630919
|
Grimaud E et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. |
2003 |
Am. J. Pathol. |
pmid:14578201
|
Alvarez L et al. |
Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. |
2003 |
Arthritis Rheum. |
pmid:12632438
|
Bord S et al. |
The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. |
2003 |
Bone |
pmid:12633785
|
Coen G et al. |
Serum leptin in dialysis renal osteodystrophy. |
2003 |
Am. J. Kidney Dis. |
pmid:14582047
|
Garber K |
Why it hurts: researchers seek mechanisms of cancer pain. |
2003 |
J. Natl. Cancer Inst. |
pmid:12783923
|
Chagraoui H et al. |
Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. |
2003 |
Exp. Hematol. |
pmid:14585373
|
Liu B et al. |
Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. |
2003 |
J. Oral Pathol. Med. |
pmid:12787044
|
Eaton CL and Coleman RE |
Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. |
2003 |
Cancer Treat. Rev. |
pmid:12787713
|
Fahrleitner-Pammer A et al. |
Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. |
2003 |
Wien. Klin. Wochenschr. |
pmid:12793029
|
Dovio A et al. |
Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. |
2003 |
Clin. Cancer Res. |
pmid:12796409
|
Flick LM et al. |
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. |
2003 |
J. Orthop. Res. |
pmid:12798068
|
Khapli SM et al. |
IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. |
2003 |
J. Immunol. |
pmid:12816992
|
Kawase Y et al. |
Bone malformations in interleukin-18 transgenic mice. |
2003 |
J. Bone Miner. Res. |
pmid:12817749
|
Kikuchi T et al. |
Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. |
2003 |
J. Dent. Res. |
pmid:12821717
|
D'Elia HF et al. |
Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. |
2003 |
Arthritis Res. Ther. |
pmid:12823855
|
Terpos E et al. |
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. |
2003 |
Blood |
pmid:12689925
|
Zheng B et al. |
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. |
2003 |
Blood |
pmid:12689928
|
Moreno JL et al. |
IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. |
2003 |
Blood |
pmid:12689929
|
Dovio A et al. |
Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. |
2003 |
J. Endocrinol. |
pmid:12697042
|
Nakano M et al. |
Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. |
2003 |
Oral Dis |
pmid:12657033
|
Ra JS et al. |
Osteoprotegerin inhibits proliferation of myeloid progenitor cells. |
2003 |
J. Hematother. Stem Cell Res. |
pmid:12662434
|
Szalay F et al. |
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. |
2003 |
J. Hepatol. |
pmid:12663228
|
Okada Y et al. |
Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. |
2003 |
J. Biol. Chem. |
pmid:12665515
|
Bell NH |
RANK ligand and the regulation of skeletal remodeling. |
2003 |
J. Clin. Invest. |
pmid:12697730
|
Eghbali-Fatourechi G et al. |
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. |
2003 |
J. Clin. Invest. |
pmid:12697741
|
Enomoto H et al. |
Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. |
2003 |
J. Biol. Chem. |
pmid:12697767
|
Nakashima T et al. |
RANKL and RANK as novel therapeutic targets for arthritis. |
2003 |
Curr Opin Rheumatol |
pmid:12707582
|
Johnson-Pais TL et al. |
Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. |
2003 |
Int. J. Cancer |
pmid:12673693
|
Zaidi M et al. |
Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. |
2003 |
J. Bone Miner. Res. |
pmid:12674320
|
Oyajobi BO and Mundy GR |
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. |
2003 |
Cancer |
pmid:12548580
|
Croucher PI et al. |
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. |
2003 |
Cancer |
pmid:12548581
|
Lipton A |
Bisphosphonates and metastatic breast carcinoma. |
2003 |
Cancer |
pmid:12548585
|
Demers LM |
Bone markers in the management of patients with skeletal metastases. |
2003 |
Cancer |
pmid:12548589
|
Body JJ et al. |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. |
2003 |
Cancer |
pmid:12548591
|
Liu JZ et al. |
[The OPG/RANKL/RANK system and bone resorptive disease]. |
2003 |
Sheng Wu Gong Cheng Xue Bao |
pmid:15971575
|
Xing L et al. |
Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. |
2003 |
J. Bone Miner. Res. |
pmid:12568403
|
Cao J et al. |
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. |
2003 |
J. Bone Miner. Res. |
pmid:12568404
|
Johnson-Pais TL et al. |
Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. |
2003 |
J. Bone Miner. Res. |
pmid:12568416
|
Clohisy JC et al. |
RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. |
2003 |
J. Orthop. Res. |
pmid:12568950
|
Fahrleitner A et al. |
Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. |
2003 |
Bone |
pmid:12584041
|
Rude RK et al. |
Magnesium deficiency: effect on bone and mineral metabolism in the mouse. |
2003 |
Calcif. Tissue Int. |
pmid:12370796
|